Follistatin-like protein 1 attenuates doxorubicin-induced cardiomyopathy by inhibiting MsrB2-mediated mitophagy
Authors:
- 2 May 2024
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 479 (7) , 1817-1831
Abstract
Doxorubicin (DOX) is a potent chemotherapeutic drug; however, its clinical use is limited due to its cardiotoxicity. Mitochondrial dysfunction plays a vital role in the pathogenesis of DOX-induced cardiomyopathy. Follistatin-like protein 1 (FSTL1) is a potent cardiokine that protects the heart from diverse cardiac diseases, such as myocardial infarction, cardiac ischemia/reperfusion injury, and heart failure. However, its role in DOX-induced cardiomyopathy is unclear. Therefore, the present study investigated whether administering recombinant FSTL1 could mitigate DOX-induced cardiomyopathy and clarified the underlying molecular mechanisms. FSTL1 treatment attenuated DOX-induced cardiac dysfunction, cardiac fibrosis, and cellular apoptosis by inhibiting excess mitochondrial matrix protein methionine sulfoxide reductase B2 (MsrB2)-mediated mitophagy. Furthermore, FSTL1 administration reduced the expression of apoptotic proteins, including MsrB2, Bax, caspase 3, mitochondrial Parkin, and LC3-II, increased myocardial ATP content, and decreased cardiac malondialdehyde levels, thus protecting mitochondrial function against DOX-induced cardiac injury. Furthermore, FSTL1 treatment protected the contractile properties of adult cardiomyocytes against DOX-induced injury in vitro. Furthermore, carbonyl cyanide m-chlorophenylhydrazone, a mitophagy inducer, impaired the protective effects of FSTL1 in DOX-treated H9c2 cardiomyocytes. In conclusion, these results show that FSTL1 is a novel therapeutic agent against DOX-induced cardiotoxicity that improves mitochondrial function and decreases mitophagy.Keywords
Funding Information
- National Natural Science Foundation of China (82000373, 82270526)
- the National Key Research and Development Program of Shaanxi Province (2023-YBSF-105)
This publication has 41 references indexed in Scilit:
- Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent mechanismBiomedicine & Pharmacotherapy, 2022
- Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective managementBiomedicine & Pharmacotherapy, 2021
- Irisin attenuates myocardial ischemia/reperfusion‐induced cardiac dysfunction by regulating ER‐mitochondria interaction through a mitochondrial ubiquitin ligase‐dependent mechanismClinical and Translational Medicine, 2020
- Mitophagy and mitochondrial integrity in cardiac ischemia-reperfusion injuryBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Mitochondrial methionine sulfoxide reductase B2 links oxidative stress to Alzheimer's disease-like pathologyExperimental Neurology, 2019
- l‐Methionine activates Nrf2‐ARE pathway to induce endogenous antioxidant activity for depressing ROS‐derived oxidative stress in growing ratsJournal of the Science of Food and Agriculture, 2019
- Rutin attenuates doxorubicin-induced cardiotoxicity via regulating autophagy and apoptosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanismBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Mitochondrial involvement in myocyte death and heart failureHeart Failure Reviews, 2016
- Follistatin‐like protein 1 enhances NLRP3 inflammasome‐mediated IL‐1β secretion from monocytes and macrophagesEuropean Journal of Immunology, 2014